DIA
PLX icon

Denver Investment Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Denver Investment Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,161
Closed -$145K – 641
2014
Q1 		$145K Buy
3,161
+1,082
+52% +$50.5K ﹤0.01% 581
2013
Q4 		$81 Hold
2,079
– – ﹤0.01% 564
2013
Q3 		$94K Buy
+2,079
New +$107K ﹤0.01% 563

Other funds holding PLX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Denver Investment Advisors's PLX Position: Q2 2014 in Review

Denver Investment Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2014, closing a stake of 3,161 shares — an estimated $145K sold.

Denver Investment Advisors first reported a position in PLX in Q3 2013 and held it in 3 quarters. The position peaked at $145K in Q1 2014. 45 funds tracked by Wall St. Rank hold PLX as of Q2 2014.

  • Denver Investment Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2014 after selling out during the quarter.
  • Denver Investment Advisors sold 3,161 Protalix BioTherapeutics shares in Q2 2014, an estimated $145K.
  • Denver Investment Advisors first reported a position in Protalix BioTherapeutics in Q3 2013 and held it in 3 quarters.
  • Denver Investment Advisors's Protalix BioTherapeutics position peaked at $145K in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2014.

Based on Denver Investment Advisors's 13F filing for Q2 2014, filed 8 Aug 2014.